Efficacy and safety of lorlatinib in Korean non-small-cell lung cancer patients with ALK or ROS1 rearrangement whose disease failed to respond to a previous tyrosine kinase inhibitor - Lee, J; Sun, J M; Lee, S H (Clin Lung Cancer, 2019)
, et al.